NIH PAR · NCI · R01
PAR-25-175: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
- NOFO number
- PAR-25-175
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Nov 6, 2024
- Opens
- Jan 5, 2025
- Expires
- Jan 8, 2028
PAR-25-175 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | May 07, 2025 * | July 2025 | October 2025 | December 2025 |
| June 05, 2025 | July 05, 2025 * | September 07, 2025 * | November 2025 | January 2026 | April 2026 |
| October 05, 2025 | November 05, 2025 * | January 07, 2026 * | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | May 07, 2026 * | July 2026 | October 2026 | December 2026 |
| June 05, 2026 | July 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 05, 2027 | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-175
NIH RePORTER lists 2 projects funded under PAR-25-175 in FY2022–FY2026, with $1.3M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$1.3M
Award dollars under PAR-25-175, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 2 | 2 | $1.3M |
Institutions with the most funding
- Mayo Clinic Rochester$668K · 1 project
- Washington University$667K · 1 project
Funding institutes
- NCI$1.3M · 2
Activity codes funded
- R012 records
Most recent new awards
- Integration of FTT-PET and ctDNA to predict response to PARP inhibitor therapy in mPC (opens NIH RePORTER)
Washington University · 1R01CA306993-01A1 · NCI · Notice Aug 27, 2026
$667KR01
- Blood-based tumor and immune markers for risk stratification and monitoring treatment response in oligometastatic prostate cancer (opens NIH RePORTER)
Mayo Clinic Rochester · 1R01CA300454-01A1 · NCI · Notice Mar 24, 2026
$668KR01
What its predecessor PAR-21-290 funded
PAR-25-175 reissues PAR-21-290. Its funding history is the best guide to who wins under this program: 7 projects and $15.7M in FY2022–FY2026.
Projects funded
7
Distinct projects, FY2022–FY2026
New awards
7
Type 1 (new project) award records
NIH funding
$15.7M
Award dollars under PAR-21-290, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 1 | 1 | $734K |
| FY2023 | 4 | 3 | $2.8M |
| FY2024 | 5 | 1 | $3.2M |
| FY2025 | 7 | 2 | $4.5M |
| FY2026 | 7 | 0 | $4.5M |
Institutions with the most funding
- Sloan-Kettering Inst Can Research$3.6M · 1 project
- Johns Hopkins University$2.7M · 1 project
- University of Tx MD Anderson Can Ctr$2.6M · 1 project
- University of Chicago$2.6M · 1 project
- University of Michigan at Ann Arbor$1.7M · 1 project
- Massachusetts General Hospital$1.4M · 1 project
- University of Miami School of Medicine$1.1M · 1 project
Funding institutes
- NCI$15.7M · 24
Activity codes funded
- R0124 records
Most recent new awards
- Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patients (opens NIH RePORTER)
Massachusetts General Hospital · 1R01CA302774-01 · NCI · Notice Aug 15, 2025
$684KR01
- Longitudinal Imaging and Liquid Biopsy Markers of Prostate Cancer Radiotherapy Outcomes (opens NIH RePORTER)
University of Miami School of Medicine · 1R01CA294824-01A1 · NCI · Notice Mar 25, 2025
$539KR01
- A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment (opens NIH RePORTER)
University of Michigan at Ann Arbor · 1R01CA278898-01A1 · NCI · Notice Nov 21, 2023
$577KR01
- Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myeloma (opens NIH RePORTER)
University of Chicago · 1R01CA280637-01 · NCI · Notice Jul 25, 2023
$692KR01
- Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy (opens NIH RePORTER)
Johns Hopkins University · 1R01CA276221-01A1 · NCI · Notice Jun 30, 2023
$691KR01
- Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1R01CA276178-01A1 · NCI · Notice Jun 8, 2023
$677KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-175. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Jan 28, 2026 · NOT-OD-26-029
NIH Removing AIDS Application Due Dates from NOFOs. See Notice NOT-OD-26-029.
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to less than 500,000 in direct costs per year and the requested amount in any year needs to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-290.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.